April 23rd 2021
The CDC's Advisory Committee on Immunization Practices voted to uphold the original language of the emergency use authorization for Johnson & Johnson's COVID-19 vaccination, and is possible the 1-dose vaccine could resume Saturday.
Cost Per Response Analysis of Strategies for Chronic Immune Thrombocytopenia
This decision tree model estimates the cost per response and incremental cost per additional responder for romiplostim, eltrombopag, and “watch and rescue” for immune thrombocytopenia.
Read More
Research Highlights Long-Term Survival and Health-Related QoL in Patients With Newly Diagnosed MM
July 6th 2018Research presented at the 2018 American Society of Clinical Oncology Annual Meeting identified predictors of long-term survival and health-related quality of life (QoL) in patients with newly diagnosed multiple myeloma (MM).
Read More
Review Finds Time to Diagnosis for Multiple Myeloma Can Be Significantly Reduced
July 5th 2018A review of studies found that the time from symptom onset to confirmation of diagnosis of multiple myeloma can be significantly reduced. Currently, many patients experience a more than 3-month delay until their diagnosis is confirmed.
Read More
Glasdegib Receives Priority Review Based on Results It Nearly Doubles OS in AML
June 30th 2018Based on trial results that showed glasdegib, an investigational oral smoothened inhibitor, nearly doubled overall survival (OS) in patients with previously untreated acute myeloid leukemia (AML), the FDA has granted the Pfizer drug a Priority Review.
Read More
Patients With Myelofibrosis Treated With JAK1/2 Inhibitors at Increased Risk of Lymphomas
June 22nd 2018Patients with myelofibrosis who were treated with Janus-kinase (JAK) 1/2 inhibitors have an increased risk for developing B-cell lymphoma. However, researchers believe there is a pre-existing B-cell clone that patients can be tested for before treatment.
Read More
Dr Michael Thompson Highlights Novel Therapies Being Used in Hematologic Malignancies
June 16th 2018Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare, outlines novel therapies being used in the treatment of hematologic malignancies and identified biomarkers for deciding on a treatment approach.
Watch
Gene Editing Could Reduce Toxicity of CAR T Treatment in AML
June 15th 2018A new approach using gene editing technology could allow chimeric antigen receptor (CAR) T cells to target CD33 in patients with acute myeloid leukemia (AML) but prevent the cells from attacking healthy stem cells, too.
Read More
Once-Weekly Carfilzomib Superior to Twice-Weekly Regimen in Relapsed/Refractory Multiple Myeloma
June 6th 2018The interim analysis of the phase 3 A.R.R.O.W. trial found that once-weekly carfilzomib at 70 mg/m2 had superior progression-free survival and overall response rates compared with twice-weekly carfilzomib at 27 mg/m2.
Read More
Analyzing Worries in Leukemia and Economic Burden in Lymphoma
June 2nd 2018Two abstracts presented at the International Society of Pharmacoeconomic and Outcomes Research Annual International Meeting highlighted patient experiences in blood cancers. One highlighted the worries of patients with acute myeloid leukemia, and the other analyzed economic burdens and resource utilization for patients with non-Hodgkin lymphoma.
Read More
Studies Highlight the Cost Burden of Diffuse Large B-Cell Lymphoma
May 31st 2018Two study abstracts presented at the International Society of Pharmacoeconomics and Outcomes Research Annual International Meeting look at the cost burden of diffuse large B-cell lymphoma (DLBCL). One analyzed the lifetime cost of relapsed/refractory DLBCL, including third-line and subsequent treatments, and the other examined how being diagnosed with DBLCL can increase the cost burden of chronic conditions among Medicare beneficiaries.
Read More
Analysis Outlines Global Burden of Multiple Myeloma, Access to Effective Treatments
May 26th 2018A new study analyzed the burden of multiple myeloma around the world, as well as access to effective treatments. From 1990 to 2016, incident cases and deaths from the disease have grown substantially.
Read More
Analysis of patient-reported outcomes found patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were treated with inotuzumab ozogamicin reported better quality of life, functioning, and symptom scores compared with patients receiving standard-of-care chemotherapies.
Read More
Study Reports Highest Survival Rates for Children, Young Adults With Certain T-Cell Leukemias
May 18th 2018A phase III randomized trial, with results being presented in June at the American Society of Clinical Oncology Annual Meeting, found the addition of nelarabine to standard chemotherapy regimen in patients with T-cell malignancies can improve disease-free survival rates.
Read More
FDA Approves Epoetin Alfa Biosimilar for Anemia
May 15th 2018The FDA has approved Pfizer’s epoetin alfa-epbx (Retacrit), a biosimilar to epoetin alfa (Epogen), marking the first biosimilar approval of 2018 and the first biosimilar erythropoiesis-stimulating agent approved in the United States.
Read More
CAR T Therapy Case Study Shows Early Success in Treatment of Acute Myeloid Leukemia
May 9th 2018A new case study found that an acute myeloid leukemia patient has remained cancer free for 9 months following treatment with the chimeric antigen receptor (CAR) T-cell treatment, CYAD-01, and a bone marrow transplant.
Read More
Daratumumab Approved as Frontline Treatment in Newly Diagnosed Multiple Myeloma
May 8th 2018The FDA has approved daratumumab in combination with bortezomib, melphalan, and prednisone to treat patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Read More